Zacks Research Issues Pessimistic Estimate for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research dropped their Q4 2025 EPS estimates for shares of Bio-Rad Laboratories in a note issued to investors on Wednesday, December 18th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $3.21 per share for the quarter, down from their prior forecast of $3.28. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2026 earnings at $3.16 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million for the quarter, compared to analysts' expectations of $628.18 million. During the same quarter in the prior year, the company earned $2.33 earnings per share. The business's revenue was up 2.8% compared to the same quarter last year.

Other equities analysts also recently issued reports about the company. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price target for the company. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an "outperform" rating in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $394.20.

Bio-Rad Laboratories Stock Down 0.8 %

BIO stock traded down $2.71 on Monday, reaching $324.76. 44,914 shares of the company traded hands, compared to its average volume of 241,926. The firm has a fifty day simple moving average of $340.72 and a 200-day simple moving average of $322.85. The company has a market cap of $9.09 billion, a P/E ratio of -11.88 and a beta of 0.90. Bio-Rad Laboratories has a one year low of $262.12 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Van ECK Associates Corp purchased a new position in shares of Bio-Rad Laboratories in the 2nd quarter worth $180,040,000. First Eagle Investment Management LLC lifted its holdings in Bio-Rad Laboratories by 32,296.9% in the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock valued at $173,773,000 after acquiring an additional 634,311 shares during the period. Point72 Asset Management L.P. purchased a new position in Bio-Rad Laboratories in the third quarter worth about $83,681,000. Dimensional Fund Advisors LP grew its stake in shares of Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company's stock valued at $135,081,000 after purchasing an additional 193,700 shares during the period. Finally, Select Equity Group L.P. increased its position in shares of Bio-Rad Laboratories by 26.2% during the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company's stock valued at $177,391,000 after purchasing an additional 134,856 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.